Blog

Advancing molecular glue technology – Asian Fund for Cancer Research

Asian Fund for Cancer Research/LinkedIn

Dec 15, 2024, 08:27

Advancing molecular glue technology – Asian Fund for Cancer Research

Asian Fund for Cancer Research posted the following on LinkedIn:

“Thanks to the long-term support of AFCR’s loyal donors, AFCR-funded scientists have made impressive progress in the fight against cancer.

Outstanding scientific research achievements in 2024 include: the first molecular glue degradation agent. Dr. Zou Lihui researched a new class of small molecule drugs developed through a molecular glue-based targeted protein degradation platform.

The proprietary platform has curated a unique and expanding library of molecular glue compounds, enabling the targeting of previously undruggable targets.

Donate to support cancer research.
Learn more.”

AIM-HI Accelerator Fund Asian Fund for Cancer Research cancer cancer innovation Cancer research Degron Therapeutics molecular glue compounds OncoDaily Oncology oncology advancements targeted therapy undruggable targets Zou Lihui

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity